Graham Walmsley is a Principal at Versant Ventures specializing in healthcare and biotechnology investing. Since joining the firm in 2016, Graham helped build and launch BlueRock Therapeutics, a cell therapy company formed in partnership with Bayer AG through one of the largest Series A financings in biotech history. Graham led Versant’s investment into Akero Therapeutics, a clinical stage NASH company, and currently serves as a director on the board. He is actively involved with several other Versant portfolio companies including roles as head of business development at both Jecure Therapeutics and Pipeline Therapeutics.
Graham concurrently earned his M.D. and Ph.D. degrees from Stanford University School of Medicine, where he was the recipient of the Kaluza Prize, Young Investigator Award, and Peter J. Gingrass Memorial Award. While a graduate student, Graham’s work was featured in Time magazine and he authored over 60 publications in journals such as Science and Cell. He graduated summa cum laude and received his B.A. from the University of California, Berkeley, with distinction in Molecular and Cell Biology.